Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vistin Pharma ASA: Invitation to Q2 2026 conference call

VISTNRegulatory press release13.08.2026 klo 11.30
Oslo, Norway, 13 August 2026

Vistin Pharma ASA (VISTN) will release its second quarter and YTD 2026 results
on Thursday 20th of August 2026. Vistin Pharma will host a conference call for
all shareholders and other interested parties on the same day at 08:30 CET.
There will be a Q&A session following the management discussion.

The second quarter conference call will be accessible via web and audio through
the following access points:

Webcast: https://edge.media-server.com/mmc/p/abe93pzc

Telephone conference (online registration):

https://register-conf.media-
server.com/register/BIca3298faa94f4bbb900f07289bc40eb7 (https://register-
conf.media-server.com/register/BI83c6eca2da3d47c3bec047d0633a0501)

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin
Hydrochloride (API). The Metformin is also available as Direct Compressible
lubricated granules. As a solely dedicated European Metformin producer, Vistin
Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin
Pharma is headquartered in Oslo, Norway, and has highly qualified employees and
a dedicated manufacturing facility in Kragerø.
icated manufacturing facility in Kragerø.\